 Metal nanoparticles, MNPs, have shown promise in cancer treatment due to their unique physical and chemical characteristics. However, these particles also present some drawbacks, including limited specificity and toxicity toward healthy cells. Hyaluronic acid, HA, a biocompatible and biodegradable polysaccharide, has been used as a targeting agent for MNPs because it binds to the CD44 receptor, which is overexpressed on many cancer cells. HA modified MNPs have shown improved specificity and efficacy compared to unmodified MNPs, suggesting that this approach could be beneficial in cancer therapies. This review provides an overview of the current status of cancer research, the role of HA modified MNPs, and other substances in cancer therapy. It also discusses the challenges associated with clinical translation of HA modified MNPs, as well as potential solutions. This article was authored by Alavangada Thamea Uthappa, Madhuru Sunitha, Kanali Vi Ajay, and others. We are article.tv, links in the description below.